← All trials
NCT05061823
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 25, 2021
- Primary completion
- Dec 20, 2024
- Completion date
- Dec 20, 2024
- First posted
- Sep 30, 2021
- Last posted
- Sep 30, 2021
- Enrollment
- 42
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Merck SeronoLead sponsor
- Merck KGaACollaborator
- Merck KGaAStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.